Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome : Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2
The coexistence of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) autoantibodies in the same individual is surprisingly often observed. We herein report the first case of LGI1 encephalitis followed by Isaacs syndrome in which LGI1 and CASPR2 antibodies in the serum and cerebrospinal fluid (CSF) were measured during the entire disease course. After the resolution of limbic encephalitis, LGI1 antibodies disappeared from the CSF simultaneously with the appearance of CASPR2 antibodies in the serum. The alternating presence of these pathogenic autoantibodies along with the clinical and phenotypic alternations suggested that LGI1 encephalitis was associated with CASPR2 autoantibody production in the peripheral tissue, leading to CASPR2-associated Isaacs syndrome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 62(2023), 11 vom: 01. Juni, Seite 1659-1663 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murayama, Aki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.06.2023 Date Revised 01.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.9670-22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347390617 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347390617 | ||
| 003 | DE-627 | ||
| 005 | 20231226033714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.9670-22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347390617 | ||
| 035 | |a (NLM)36223927 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murayama, Aki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome |b Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.06.2023 | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The coexistence of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) autoantibodies in the same individual is surprisingly often observed. We herein report the first case of LGI1 encephalitis followed by Isaacs syndrome in which LGI1 and CASPR2 antibodies in the serum and cerebrospinal fluid (CSF) were measured during the entire disease course. After the resolution of limbic encephalitis, LGI1 antibodies disappeared from the CSF simultaneously with the appearance of CASPR2 antibodies in the serum. The alternating presence of these pathogenic autoantibodies along with the clinical and phenotypic alternations suggested that LGI1 encephalitis was associated with CASPR2 autoantibody production in the peripheral tissue, leading to CASPR2-associated Isaacs syndrome | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Isaacs syndrome | |
| 650 | 4 | |a autoantibodies | |
| 650 | 4 | |a contactin-associated protein-like 2 (CASPR2) | |
| 650 | 4 | |a leucine-rich glioma-inactivated 1 (LGI1) | |
| 650 | 4 | |a limbic encephalitis | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Leucine |2 NLM | |
| 650 | 7 | |a GMW67QNF9C |2 NLM | |
| 650 | 7 | |a Intracellular Signaling Peptides and Proteins |2 NLM | |
| 650 | 7 | |a Contactins |2 NLM | |
| 700 | 1 | |a Sugaya, Keizo |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Kawazoe, Tomoya |e verfasserin |4 aut | |
| 700 | 1 | |a Tobisawa, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nakajima, Hideto |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Kazushi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 62(2023), 11 vom: 01. Juni, Seite 1659-1663 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:11 |g day:01 |g month:06 |g pages:1659-1663 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.9670-22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 11 |b 01 |c 06 |h 1659-1663 | ||